Get started
Author

Nicholas A. Zorko

Observed names: N A Zorko, N. Zorko, N.A. Zorko, Nicholas A Zorko, Nicholas Zorko
Observed institutions: University of Minnesota, Nationwide Children's Hospital, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Masonic Cancer Center, Abigail Wexner Research Institute, The Ohio State University
ORCID: 0000-0001-7021-968X
Observed ORCID: 0000-0001-7021-968X
OpenAlex ID: A5014166747
NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
2020 · Daniel A. Vallera, Soldano Ferrone, et al. · Cancers · 95
PDF
Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias
2012 · Nicholas A. Zorko, Kelsie M. Bernot, et al. · Blood · 95
Heparin-Binding EGF-Like Growth Factor Increases Intestinal Microvascular Blood Flow in Necrotizing Enterocolitis
2009 · Xiaoyi Yu, Andrei Radulescu, et al. · Gastroenterology · 85
PDF
MicroRNA-29b mediates altered innate immune development in acute leukemia
2016 · Bethany L. Mundy-Bosse, Steven D. Scoville, et al. · Journal of Clinical Investigation · 77
PDF
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis
2012 · Hannah E. Cummings, Joseph Barbi, et al. · Proceedings of the National Academy of Sciences · 56
PDF
Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4
2026 · Andrew J. Armstrong, Michael J. Morris, et al. · Journal of Clinical Oncology · 45
PDF
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells
2012 · Yue Zhang, Xiaomei Yan, et al. · Blood · 37
Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond
2023 · Sree M. Lanka, Nicholas A. Zorko, et al. · Current Oncology · 34
PDF
Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease
2013 · Kelsie M. Bernot, John S. Nemer, et al. · Blood · 34
Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies
2024 · Carly D. Miller, John R. Lozada, et al. · Cancer Research Communications · 32
PDF
Preclinical Neonatal Rat Studies of Heparin-Binding EGF-Like Growth Factor in Protection of the Intestines From Necrotizing Enterocolitis
2009 · Andrei Radulescu, Nicholas A Zorko, et al. · Pediatric Research · 32
PDF
Quantitative measurements of NO reaction kinetics with a Clark-type electrode
2005 · Xiaoping Liu, Qihui Liu, et al. · Nitric Oxide · 31
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes
2024 · Nicholas A. Zorko, Allison Makovec, et al. · Prostate Cancer and Prostatic Diseases · 29
PDF
Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer
2022 · Xiaolei Shi, Abderrahman Day, et al. · npj Precision Oncology · 24
PDF
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
2021 · Nicholas A. Zorko, Charles J. Ryan · Prostate Cancer and Prostatic Diseases · 21
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting
2025 · John R. Lozada, Andrew Elliott, et al. · Cancer Research Communications · 17
PDF
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancer
2025 · Melissa J Khaw, Nicholas A Zorko, et al. · Journal for ImmunoTherapy of Cancer · 13
PDF
Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML
2013 · K M Bernot, R F Siebenaler, et al. · Leukemia · 13
Biphasic modulation of vascular nitric oxide catabolism by oxygen
2004 · Xiaoping Liu, Crystal Cheng, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 12
A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
2024 · Shee Kwan Phung, Nicholas A. Zorko, et al. · Cancer Immunology Research · 10
PDF
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer
2024 · Hannah E. Bergom, Laura A. Sena, et al. · npj Genomic Medicine · 9
PDF
755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells
2022 · J.S. Miller, N. Zorko, et al. · Annals of Oncology · 9
PDF
Abstract 2761: FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3
2022 · Nicholas Zorko, Frank Cichocki, et al. · Cancer Research · 9
A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.
2024 · Gary Edward Richardson, Ganessan Kichenadasse, et al. · Journal of Clinical Oncology · 7
PDF
965MO GTB-3550 tri-specific killer engager safely activates and delivers IL-15 to NK cells, but not T-cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3
2021 · J.S. Miller, E.D. Warlick, et al. · Annals of Oncology · 5
Works count: 156
Citation count: 874
H-index: 16
I10-index: 20
Year
Topic
Type